Skip to main content

Compugen Ltd. (CGEN) Stock Forecast

Data as of Aug 8, 2026

Healthcare · Current price $2.42 (+5.00%)

Consensus Target
$4.50
Upside
+107.0%
Analysts
1
Rating
Buy(2.00)

Price Target Range

Low $4.00Consensus $4.50High $5.00
▲ Current $2.42

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

CGEN vs Sector & Market

MetricCGENHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count1818
Target Upside+107.0%+16286.3%+14.7%
P/E Ratio7.283.5836.06

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$1M$2M$2M1
2026-12-31$6M$6M$7M2
2027-03-31$1M$1M$1M1
2027-06-30$1M$1M$1M2
2027-09-30$1M$1M$1M2
2027-12-31$1M$1M$1M1
2028-12-31$25M$41M$56M5
2029-12-31$30M$48M$66M2
2030-12-31$36M$58M$79M2

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$-0.08$-0.07$-0.071
2026-12-31$-0.03$-0.03$-0.031
2027-03-31$-0.09$-0.08$-0.081
2027-06-30$-0.09$-0.09$-0.081
2027-09-30$-0.10$-0.09$-0.091
2027-12-31$-0.10$-0.09$-0.091
2028-12-31$-0.31$-0.21$-0.115
2029-12-31$-0.42$-0.28$-0.141
2030-12-31$-0.24$-0.16$-0.081

Frequently Asked Questions

What is the analyst consensus for CGEN?

The consensus among 1 analysts covering Compugen Ltd. (CGEN) is Buy with an average price target of $4.50.

What is the highest price target for CGEN?

The highest analyst price target for CGEN is $5.00.

What is the lowest price target for CGEN?

The lowest analyst price target for CGEN is $4.00.

How many analysts cover CGEN?

1 analysts have issued ratings for Compugen Ltd. in the past 12 months.

Is CGEN a buy or sell right now?

Based on 1 analyst ratings, CGEN has a consensus rating of Buy (2.00/5) with a +107.0% upside to the consensus target of $4.50.

What are the earnings estimates for CGEN?

Analysts estimate CGEN will report EPS of $-0.07 for the period ending 2026-09-30, with revenue estimated at $2M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.